105
Participants
Start Date
June 24, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Dexamethasone sodium phosphate
Dexamethasone sodium phosphate encapsulated in autologous erythrocytes and administered via IV infusion
Placebo
Placebo encapsulated in autologous erythrocytes and administered via IV infusion
Copenhagen University Hospital, Rigshospitalet, Department of Pediatric Neurology, Copenhagen
The Johns Hopkins Hospital, Division of pediatric allergy and immunology, Baltimore
Spedali Civili di Brescia, Pediatric immunology department, Brescia
Hospital Universitario La Paz, Department of pediatric neurology, Madrid
Cincinnati Children's Hospital, Division of neurology, Cincinnati
University Hospital Frankfurt, Pediatric and Adolescent Clinic, Frankfurt
IKF Pneumologie GmbH & Co. KG; Institut für klinische Forschung Pneumologie Clinical Research Center Respiratory Diseases, Frankfurt
UT Health Houston, Department of pediatrics, division of child & adolescent neurology, Houston
University of California Los Angeles (UCLA), Ataxia Center and HD Center of excellence, Los Angeles
Policlinico Umberto I, La sapienza University, Department of neurosciences and menthal health, Roma
Oslo University Hospital, Rikshospitalet, Division of Pediatric and Adolescent Medicine, Norwegian National Unit for Newborn Screening, Oslo
MedPolonia sp zoo, Poznan
"Instytut Pomnik-Centrum Zdrowia Dziecka, Immunology clinic", Warsaw
Hospital Universitari Vall d'Hebron, Department of pediatric neurology, Barcelona
University Children's Hospital Zürich - Eleonore Foundation, Zurich
University Hospitals Birmingham NHS Foundation Trust, Birmingham
St George's University Hospitals NHS Foundation Trust, Centre for Neonatal and Paediatric Infection, London
Great Ormond Street Hospital for Children, Zayed Centre for Research, London
Nottingham Children's Hospital, Queen's Medical Center, Children's neurology, Nottingham
Collaborators (1)
Biotrial
INDUSTRY
Quince Therapeutics S.p.A.
INDUSTRY